Investor Centre

Pharmaxis (ASX: PXS) today announced that, on this occasion, its new drug for treating cystic fibrosis, Bronchitol, has not been recommended for listing on the Australian Pharmaceutical Benefits Scheme by the government’s expert advisory body, the Pharmaceutical Benefits Advisory Committee (PBAC). 

Pharmaxis has been verbally advised of the decision made at the Committee’s November meeting, the minutes of which will be published on the PBAC website next month.  Pharmaxis will meet with the Chair of PBAC in early December to discuss the outstanding concerns of the Committee.